풍전약품

298060KOSDAQ

58.3 / 100

Reference Date: 2026-09-08

Financial Score20.5 / 40

News Sentiment18.8 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly down 1.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

SCM Life Science is a biotech company that develops high-purity stem cell therapeutics using its proprietary layer separation culture technology. It is conducting clinical trials for treatments targeting chronic graft-versus-host disease, acute pancreatitis, and atopic dermatitis. Additionally, it has launched the dermocosmetic brand 'Iroro,' leveraging CXCL1 protein and hPL cultivation technology, and is expanding globally through international sales agreements.

Number of Employees

25people

Average Salary

37.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

420.83Industry Average 15.000.0Point

28.1x industry avg (risky)

PBR

0.67Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

0.81Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

7.36Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲1404.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲36.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -59.1% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Positive
삼양컴텍, 상장 1년 락업 해제?최대주주 지분 58%
삼양컴텍의 최대주주 지분이 락업 해제되어 시장에 대규모 자금 유입이 예상되며, 이는 회사의 성장 가능성을 높이는 요인으로 작용할 것으로 보인다.

Detailed Momentum

52-week position5.0Point

52w mid range (59%)

Current 2,525Won52-week high 3,70552-week low 764

1-month return3.0Point

1m -1.37% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14